Literature DB >> 23022017

Recombinant Leishmania (Leishmania) infantum Ecto-Nucleoside Triphosphate Diphosphohydrolase NTPDase-2 as a new antigen in canine visceral leishmaniasis diagnosis.

Ronny Francisco de Souza1, Yaro Luciolo Dos Santos, Raphael de Souza Vasconcellos, Lucas Borges-Pereira, Ivo Santana Caldas, Márcia Rogéria de Almeida, Maria Terezinha Bahia, Juliana Lopes Rangel Fietto.   

Abstract

Canine visceral leishmaniasis is an important public health concern. In the epidemiological context of human visceral leishmaniasis, dogs are considered the main reservoir of Leishmania parasites; therefore, dogs must be epidemiologically monitored constantly in endemic areas. Furthermore, dog to human transmission has been correlated with emerging urbanization and increasing rates of leishmaniasis infection worldwide. Leishmania (Leishmania) infantum (L. chagasi) is the etiologic agent of visceral leishmaniasis in the New World. In this work, a new L. (L.) infantum (L. chagasi) recombinant antigen, named ATP diphosphohydrolase (rLic-NTPDase-2), intended for use in the immunodiagnosis of CVL was produced and validated. The extracellular domain of ATP diphosphohydrolase was cloned and expressed in the pET21b-Escherichia coli expression system. Indirect ELISA assays were used to detect the purified rLic-NTPDase-2 antigen using a standard canine sera library. This library contained CVL-positive samples, leishmaniasis-negative samples and samples from Trypanosoma cruzi-infected dogs. The results show a high sensitivity of 100% (95% CI=92.60-100.0%) and a high specificity of 100% (95% CI=86.77-100.0%), with a high degree of confidence (k=1). These findings demonstrate the potential use of this recombinant protein in immune diagnosis of canine leishmaniasis and open the possibility of its application to other diagnostic approaches, such as immunochromatography fast lateral flow assays and human leishmaniasis diagnosis.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23022017     DOI: 10.1016/j.actatropica.2012.09.011

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  5 in total

1.  Novel recombinant multiepitope proteins for the diagnosis of asymptomatic leishmania infantum-infected dogs.

Authors:  Angélica Rosa Faria; Luciano de Castro Veloso; Wendel Coura-Vital; Alexandre Barbosa Reis; Leonardo Miranda Damasceno; Ricardo T Gazzinelli; Hélida M Andrade
Journal:  PLoS Negl Trop Dis       Date:  2015-01-08

2.  Leishmania infantum ecto-nucleoside triphosphate diphosphohydrolase-2 is an apyrase involved in macrophage infection and expressed in infected dogs.

Authors:  Raphael De Souza Vasconcellos; Christiane Mariotini-Moura; Rodrigo Saar Gomes; Tiago Donatelli Serafim; Rafaela de Cássia Firmino; Matheus Silva E Bastos; Felipe Freitas de Castro; Claudia Miranda de Oliveira; Lucas Borges-Pereira; Anna Cláudia Alves de Souza; Ronny Francisco de Souza; Gabriel Andres Tafur Gómez; Aimara da Costa Pinheiro; Talles Eduardo Ferreira Maciel; Abelardo Silva-Júnior; Gustavo Costa Bressan; Márcia Rogéria Almeida; Munira Muhammad Abdel Baqui; Luís Carlos Crocco Afonso; Juliana Lopes Rangel Fietto
Journal:  PLoS Negl Trop Dis       Date:  2014-11-13

3.  Development of a Multi-Epitope Recombinant Protein for the Diagnosis of Human Visceral Leishmaniasis.

Authors:  Farnoosh Jameie; Abdolhossein Dalimi; Majid Pirestani; Mehdi Mohebali
Journal:  Iran J Parasitol       Date:  2021 Jan-Mar       Impact factor: 1.012

4.  Application of Recombinant Proteins for Serodiagnosis of Visceral Leishmaniasis in Humans and Dogs.

Authors:  Mahin Farahmand; Hossein Nahrevanian
Journal:  Iran Biomed J       Date:  2016-02-17

5.  Infection of Human Macrophages by Leishmania infantum Is Influenced by Ecto-Nucleotidases.

Authors:  Nalu Teixeira de Aguiar Peres; Luana Celina Seraphim Cunha; Meirielly Lima Almeida Barbosa; Márcio Bezerra Santos; Fabrícia Alvise de Oliveira; Amélia Maria Ribeiro de Jesus; Roque Pacheco de Almeida
Journal:  Front Immunol       Date:  2018-01-11       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.